Harvard Pilgrim Weighing Prilosec Promotion In Face Of Less Expensive PPIs

Harvard Pilgrim Health Care is weighing the benefits of promoting AstraZeneca's Prilosec (omeprazole) within the managed care organization's network in the face of near-term patent expiration and less costly proton pump inhibitors.